KemPharm Inc. (KMPH) Stock Price Down 3.9%
KemPharm Inc. (NASDAQ:KMPH) shares traded down 3.9% on Tuesday . The stock traded as low as $3.97 and last traded at $3.98, with a volume of 62,497 shares. The stock had previously closed at $4.14.
Several research analysts have weighed in on the company. Canaccord Genuity restated a “buy” rating on shares of KemPharm in a research note on Tuesday, May 3rd. Royal Bank Of Canada dropped their price target on KemPharm from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, May 6th. Zacks Investment Research downgraded KemPharm from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Finally, Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of KemPharm in a report on Wednesday, June 8th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $26.80.
The stock has a 50 day moving average of $4.12 and a 200 day moving average of $10.60. The stock’s market cap is $55.89 million.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.36. Equities analysts predict that KemPharm Inc. will post ($2.79) earnings per share for the current fiscal year.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.